Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

NCT ID: NCT03732768

Last Updated: 2025-08-22

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-08
• Study Completion Date: 2025-08-31

Brief Summary

RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first).

In the expansion cohort the subject will receive the recommended dose. The expansion cohort will be conducted at 4 sites. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first).

Detailed Description

The maximum number of subjects enrolled in this study is 49.

The following number of subjects will be recruited in the different cohorts:

• Dose escalation cohorts: 3 - 24 Subjects
• Expansion cohort: Up to 25 Subjects

Conditions

Peritoneal Carcinomatosis; Ovarian Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Radspherin

Group Type: EXPERIMENTAL

Radspherin

Intervention Type: DRUG

Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.

Interventions

Radspherin

Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Able and willing to provide written informed consent and to comply with the clinical study protocol

2. Age ≥ 18 years

3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal carcinoma

4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking surgery to R0.

5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy at time of first administration of Radspherin®

6. ECOG Performance Status Score of 0 - 1

7. Adequate renal function

• Creatinine ≤ 1.8 mg/dl (159 μmol/l) and
• calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or
• measured creatinine clearance ≥ 45 ml/min

8. Adequate hepatic function

• Serum bilirubin <1.5 x upper limit of normal (ULN)
• Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN

9. Adequate bone marrow function:

• Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/l
• Platelets ≥ 100 x 10^9/l
• Haemoglobin ≥ 9 g/dL

10. Adequate coagulation tests: INR ≤ 1.5 x ULN

11. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment

12. For females of childbearing potential who have a male partner: agreement to use two adequate methods of contraception (e.g. barrier, intrauterine device, hormonal implants, combined oral contraceptives or vasectomized partner), during the treatment period and for at least 3 months after the last dose of IMP.

Exclusion Criteria

1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors, Sex-cord tumors)

2. Tumors of borderline malignancy

3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic lymph nodes are acceptable, except thoracic lymph nodes.

4. Pregnant or lactating (nursing) women

5. Active infections requiring antibiotics, and/or physician monitoring or recurrent fever >38.0 ⁰C associated with a clinical diagnosis of active infection

6. Active liver disease with positive serology for active hepatitis B, hepatitis C or known HIV

7. Administration of an investigational medicinal product within 28 days, or at least 5 times the half-life, prior to enrolment

8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the last study treatment

9. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer)

10. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease

11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise the safety of the subjects or interfere with the evaluation of the safety of the IMP

12. In the Investigator's opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent

13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS

14. Known hypersensitivity to any of the excipients in the study drug

15. Persons who have been placed in an institution under an official or judicial order

16. Persons who are dependent on the sponsor financially must be excluded from participation

17. Persons with active SARS-CoV-2 infection must be excluded from participation

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Oncoinvent AS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UZ Leuven

Leuven, , Belgium

The Norwegian Radiumhospital

Oslo, , Norway

Clínica Universidad de Navarra

Madrid, , Spain

Clínica Universidad de Navarra

Pamplona, , Spain

Countries

Belgium; Norway; Spain

Other Identifiers

2018-002802-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

RAD-18-001

Identifier Type: -

Identifier Source: org_study_id